Pair Name | Polyphyllin I, Palbociclib | ||
Phytochemical Name | Polyphyllin I (PubChem CID: 72960700 ) | ||
Anticancer drug Name | Palbociclib (PubChem CID: 5330286 ) | ||
Structure of Phytochemical |
Download
2D
MOL
3D
MOL
|
||
Structure of Anticancer Drug |
Download
2D
MOL
3D
MOL
|
Pair Name | Polyphyllin I, Palbociclib | |||
Disease Info | [ICD-11: 2C25] | Lung cancer | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Up-regulation | Cleavage | CASP3 | hsa836 |
Down-regulation | Expression | CCNE1 | hsa898 | |
Down-regulation | Phosphorylation | CDK2 | hsa1017 | |
Down-regulation | Phosphorylation | CDK4 | hsa1019 | |
Down-regulation | Phosphorylation | CDK6 | hsa1021 | |
Up-regulation | Expression | CDKN1A | hsa1026 | |
Down-regulation | Phosphorylation | RB1 | hsa5925 | |
In Vitro Model | A-549 | Lung adenocarcinoma | Homo sapiens (Human) | CVCL_0023 |
NCI-H460 | Lung large cell carcinoma | Homo sapiens (Human) | CVCL_0459 | |
In Vivo Model | A549 cells (3×10⁶) in 0.2 mL medium were injected subcutaneously into the right flank of each nude mice. | |||
Result | We first time demonstrated PPI can disturb CDK2 function through upregulation of p21. The PPI effect on CDK2 provides a choice for a chemotherapeutic strategy for the elimination of NSCLC. Our study highlighted the clinical significance of simultaneously blocking of CDK2 and CDK4/6 for NSCLC treatment. |
No. | Title | Href |
---|---|---|
1 | Polyphyllin I, a lethal partner of Palbociclib, suppresses non-small cell lung cancer through activation of p21/CDK2/Rb pathway in vitro and in vivo. Cell Cycle. 2021 Dec;20(23):2494-2506. doi: 10.1080/15384101.2021.1991121. | Click |